The Food and Drug Administration accepted an Investigational New Drug application for MB-109, a novel agent that combines two mechanisms to treat recurrent glioblastoma and high-grade astrocytroma.
Craig Conlee turned to running as part of his recovery after major surgery to remove a brain tumor a year ago. Now he's running the Marine Corps Marathon.